WO2016114634A3 - 사이클램 유도체 화합물 및 이의 약학적 용도 - Google Patents

사이클램 유도체 화합물 및 이의 약학적 용도 Download PDF

Info

Publication number
WO2016114634A3
WO2016114634A3 PCT/KR2016/000478 KR2016000478W WO2016114634A3 WO 2016114634 A3 WO2016114634 A3 WO 2016114634A3 KR 2016000478 W KR2016000478 W KR 2016000478W WO 2016114634 A3 WO2016114634 A3 WO 2016114634A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivative compound
pharmaceutical use
cyclam derivative
drug
cyclam
Prior art date
Application number
PCT/KR2016/000478
Other languages
English (en)
French (fr)
Other versions
WO2016114634A2 (ko
Inventor
오유경
김진영
한정훈
김건우
Original Assignee
서울대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교 산학협력단 filed Critical 서울대학교 산학협력단
Priority claimed from KR1020160005420A external-priority patent/KR101759688B1/ko
Publication of WO2016114634A2 publication Critical patent/WO2016114634A2/ko
Publication of WO2016114634A3 publication Critical patent/WO2016114634A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 사이클램 유도체 화합물 및 이의 약제학적 용도에 관한 것으로, 상기 사이클램 유도체 화합물은 암 세포 표면에서 과발현되는 CXCR4를 선택적으로 인지하여 효율적인 약물 전달이 가능하고, 비선택적인 약물 전달의 독성을 감소시킬 뿐 아니라 표적세포에서의 약물의 효과를 증강시킬 수 있어 약물의 부작용을 완화할 수 있다.
PCT/KR2016/000478 2015-01-16 2016-01-15 사이클램 유도체 화합물 및 이의 약학적 용도 WO2016114634A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150008178 2015-01-16
KR10-2015-0008178 2015-01-16
KR10-2016-0005420 2016-01-15
KR1020160005420A KR101759688B1 (ko) 2015-01-16 2016-01-15 사이클램 유도체 화합물 및 이의 약학적 용도

Publications (2)

Publication Number Publication Date
WO2016114634A2 WO2016114634A2 (ko) 2016-07-21
WO2016114634A3 true WO2016114634A3 (ko) 2016-10-27

Family

ID=56406548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/000478 WO2016114634A2 (ko) 2015-01-16 2016-01-15 사이클램 유도체 화합물 및 이의 약학적 용도

Country Status (1)

Country Link
WO (1) WO2016114634A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107586280B (zh) * 2017-11-03 2019-12-06 梯尔希（南京）药物研发有限公司 一种普乐沙福杂质的制备方法
CN111712468A (zh) * 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
US20090202435A1 (en) * 2004-09-23 2009-08-13 Guerbet Diagnostic compounds for targeting a chemokine receptors
KR20110039557A (ko) * 2008-07-18 2011-04-19 바이엘 쉐링 파마 악티엔게젤샤프트 포스파티딜세린과의 결합을 위한 시클릭 폴리아민
US20140243397A1 (en) * 2011-10-14 2014-08-28 Wayne State University Cxcr4 inhibiting carriers for nucleic acid delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202435A1 (en) * 2004-09-23 2009-08-13 Guerbet Diagnostic compounds for targeting a chemokine receptors
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
KR20110039557A (ko) * 2008-07-18 2011-04-19 바이엘 쉐링 파마 악티엔게젤샤프트 포스파티딜세린과의 결합을 위한 시클릭 폴리아민
US20140243397A1 (en) * 2011-10-14 2014-08-28 Wayne State University Cxcr4 inhibiting carriers for nucleic acid delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LE BON, B. ET AL.: "AMD3100 Conjugates as Components of Targeted Nonvira] Gene Delivery Systems: Synthesis and in Vitro Transfecticn Efficiency of CXCR4-Expressing Cells", BIOCONJUGATE CHEM., vol. 15, no. 2, 2004, pages 413 - 423, XP002398953 *

Also Published As

Publication number Publication date
WO2016114634A2 (ko) 2016-07-21

Similar Documents

Publication Publication Date Title
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
WO2015179691A3 (en) Cell penetrating peptides and methods of making and using thereof
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
PH12016501702B1 (en) Pyrazole amide derivative
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2015035102A3 (en) Compositions and methods for the treatment of fungal infections
PH12019550249A1 (en) Solid compositions for oral administration
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
WO2016133903A3 (en) Combination therapy for cancer treatment
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
WO2014153495A9 (en) Novel stat3 inhibitors
CO2017004784A2 (es) Isómeros de ácido-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil]metil]-2-metil-piperidin-4-carboxílico como inhibidores de la cinasa aurora a
WO2015038644A3 (en) Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии
MX2020012989A (es) Agente terapeutico para la fibrosis.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
WO2018213464A3 (en) INHIBITION OF PHO84 PHOSPHATE CARRIER OF FUNGAL CELL SURFACE
WO2016130581A8 (en) Combination cancer therapy
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
WO2016114634A3 (ko) 사이클램 유도체 화합물 및 이의 약학적 용도
EA201890744A1 (ru) Фармацевтическая композиция, содержащая 8-[(3r)-3-амино-1-пиперидинил]-7-(2-бутин-1-ил)-3,7-дигидро-3-метил-1-[(4-метил-2-хиназолинил)метил]-1h-пурин-2,6-дион или его фармацевтически приемлемую соль

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16737598

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16737598

Country of ref document: EP

Kind code of ref document: A2